MR1 and melanoma: The improved efficacy of 7G5.TCR-T in the solid tumor model compared with the disseminated leukemic model was likely due to the differences in aggressiveness of in vivo growth between the cell lines but also to the fact that the melanoma model was overexpressing MR1, leading to likely supraphysiological levels of cell surface expression.